By Beckie Fenrick, PharmD, MBA Navigating the evolving rebate landscape requires in-depth expertise, especially as regulatory changes and PBM strategies […]
The biosimilar landscape is continuing to rapidly evolve, and 2025 marks a pivotal year for payers seeking cost-saving opportunities. With Stelara biosimilars making their debut and Humira biosimilars continuing to gain traction, plan sponsors will have more options than ever to control costs while ensuring members have access to the essential therapies they need.
AlignRx Consulting, a leader in the pharmacy benefit consulting space, is rebranding as Navion, reflecting the company’s evolution in delivering industry-leading pharmacy benefit solutions.
A year after implementing the solution, the group has saved $425,000 between pharmacy and medical Rx costs with minimal member disruption.
Download “A Broker’s Guide to Pharmacy Coalitions,” for the expertise and insights you need to make strategic choices.
As the pipeline of drugs for diabetes management continues to grow, benefit partners and advisors and the employer groups they serve are positioned to influence significant decisions that will impact healthcare spending.
Beckie Fenrick, Chief Pharmacy Officer, leverages her expertise to help health plans, employers, and PBMs achieve better pharmacy outcomes.
Not all coalitions are created equal, and understanding what to look for can make the difference between a beneficial partnership and a missed opportunity.
Through our RFP process, we achieved a 26% improvement in pricing and rebates for a client.
NEW YORK, August 15, 2024 – Inc. revealed today that AlignRx ranks No. 1411 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America.